Abstract：Objective To explore the methods and effect of clinical pharmacists′ participating in the clinical pathway management of ovarian benign tumors by PDCA circulation.Methods From November 2018 to October 2019, 120 inpatients with ovarian benign tumor who met the criteria of clinical pathway of ovarian benign tumor were selected as the study objects, according to the method of random number table, they were divided into the observation group and the control group, 60 cases in each group.The routine clinical pathway management of ovarian benign tumor was implemented in the control group, and the PDCA cycle clinical pathway management of clinical pharmacists was implemented in the observation group.The observation group was divided into the observation group 1 and the observation group 2 according to the different cycle, 30 cases in the each group.The first PDCA cycle was implemented in the observation group 1 (from November 2018 to April 2019), and the second PDCA cycle was implemented in the observation group 2 (from May to October 2019).The cost condition, auxiliary medication condition, rational use of prophylactic antibiotics and follow-up compliance of patients in the each group were recorded.Results There was no statistically significant difference in the length of hospital stay among the three groups (P＞0.05); the hospitalization cost of the observation group 2 was lower than that of the observation group 1 and the control group, and the differences were statistically significant (P＜0.05); there was no statistically significant difference in hospitalization expenses between the observation group 1 and the control group (P＞0.05); in terms of drug costs, the control group＞observation 1 group＞observation 2 groups, the differences among the three groups were statistically significant (P＜0.05).Observation group 1 and observation group 2 had fewer auxiliary medication costs and medication varieties than the control group, and the differences were statistically significant (P＜0.05); and observation 2 groups had fewer auxiliary medication costs and medication varieties than observation 1 group, the differences were statistically significant (P＜0.05).The reasonable rate of antimicrobial use in observation group 1 and observation group 2 was all higher than that in the control group, and the differences were statistically significant (P＜0.05); follow-up compliance rate of observation group 1 was higher than that in the the control group, the difference was statistically significant (P＜0.05); there was no statistically significant difference between the observation group 2 and the control group in follow-up compliance rate (P＞0.05); there was no statistically significant difference between the observation group 1 and the observation group 2 in the reasonable rate of antimicrobial use and follow-up compliance rate(P＞0.05).Conclusion The PDCA method to continuously optimize the clinical pharmacist′s participation in clinical path management can better standardize clinical medication and ensure patients′ safe medication.After the second cycle, hospitalization costs, drug costs, auxiliary drug costs, and the number of drug types have all been further optimized, showing that continuous optimization management is essential.
京公网安备 11010502046607号